AbbVie Inc.

- AbbVie anticipates adjusted net interest expense of $2 billion in 2024 to finance the ImmunoGen and Cerevel transactions. - The company expects an increase in adjusted earnings per share dilution of $0.42 related to the recently closed acquisition of ImmunoGen and the pending acquisition of Cerevel. - No explicit mention of new fundraising via equity or additional debt offerings beyond financing these acquisitions is provided in the available information. - The financial outlook and commentary focus on managing existing financing related to recent acquisitions rather than initiating new fundraising rounds.

- AbbVie recently completed the acquisition of ImmunoGen, which accelerates their entry into the solid tumor market and strengthens their oncology pipeline. - The integration of ImmunoGen into AbbVie has been seamless, with positive remarks on the talent brought in. - They have a pending acquisition of Cerevel, expected to close mid-year, which will augment their neuroscience portfolio with differentiated assets. - AbbVie continues to advance their early-stage pipeline and strategic development opportunities, adding novel programs and partnerships in oncology and immunology. - Investment in aesthetics includes the launch of Juvederm Voluma XC for temple hollows, strengthening leadership in that segment. - Ongoing investment in consumer activation and new product launches in China for their aesthetics business, anticipating market recovery in H2 2024.

- AbbVie expects robust revenue growth in 2025 and accelerating growth beyond 2026, driven by expanding margins and strong product performance. - Ex-Humira platform revenue grew over 15% in Q1 2024, highlighting diversified growth drivers including Skyrizi, Rinvoq, Venclexta, and Vraylar. - Skyrizi shows exceptional momentum with operational growth of 48% and leadership in psoriasis; strong uptake in IBD and upcoming launch in ulcerative colitis expected to add significant sales. - The company foresees continued volume and market share gains in immunology despite Humira exclusivity loss, with anticipated favorable payer contracts sustaining access. - Aesthetics business expects near-term negative market trends in China, with recovery beginning in second half of 2024 and ongoing investments planned. - Long-term outlook includes a high single-digit revenue CAGR through the end of the decade, supported by pipeline and recent acquisitions (e.g., ImmunoGen, Cerevel).

- Expect robust revenue growth in 2025 with acceleration in 2026 and beyond, driven by Part D benefit redesign. - Operating margin expected to expand, typically leading to faster earnings growth than revenue growth. - Exception in 2025: slight drag on earnings growth due to net interest expense, though still solid earnings growth expected. - Adjusted EPS guidance raised to $11.13 - $11.33 for 2024, exceeding prior guidance by $0.16. - Strong top and bottom-line Q1 2024 results with adjusted EPS of $2.31, $0.11 above guidance. - High-single-digit revenue compound annual growth rate (CAGR) targeted through end of the decade. - Diversified portfolio and new product launches (e.g., Skyrizi, Rinvoq, Elahere) to sustain growth momentum and earnings expansion.

The transcript provided does not contain specific information regarding current or expected orderbook or pending orders for AbbVie. The discussion primarily focuses on: - Pricing dynamics and rebates related to Humira, particularly with CVS formulary changes. - Contracting strategies and market performance of products like Skyrizi, Rinvoq, Botox, Juvederm, and biosimilar adoption. - Market outlook for aesthetics in China facing economic headwinds. - Sales and royalties concerning Skyrizi and Elahere. - Competitive market positions and growth expectations for various drugs. No explicit details on orderbook size, pending orders, or backlog volumes are mentioned in the provided pages.